Pilar Alonso, MD
Infectious Disease · Wareham, MANPI 1841295748
Payments from drug & device makers
Across 77 payments — averaging $401.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$30K
- Johnson & Johnson$211
- Janssen Products, LP$183
- W. L. Gore & Associates, Inc.$148
- Mallinckrodt Enterprises LLC$122
- Hologic Sales And Service, LLC$120
- plus $400 from 8 others
What the payments were for
- Speaking & faculty fees$25,87084%
- Travel & lodging$2,6309%
- Food & beverage$2,2607%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 42 | $29,704 |
| Johnson & Johnson(2 entities) | 7 | $211 |
| Janssen Products, LP | 2 | $183 |
| W. L. Gore & Associates, Inc. | 1 | $148 |
| Mallinckrodt Enterprises LLC | 1 | $122 |
| Hologic Sales And Service, LLC | 1 | $120 |
| Merck | 7 | $101 |
| Napo Pharmaceuticals Inc | 5 | $76 |
| AbbVie | 3 | $61 |
| Viiv Healthcare Company | 3 | $56 |
| Scilex Pharmaceuticals Inc. | 1 | $44 |
| Insmed, Inc. | 2 | $29 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Indivior Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$13,645
- GORE EXCLUDER AAA Endoprosthesis$148
- OFIRMEV$122
- Cervical Cancer Screening$120
How this compares
$30,888 in reported general payments places this provider in the 80th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 22 | $98 |
| Doxycycline Hyclate | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Wareham
- Dan BarouchBoston$35.8M
- Shahin LockmanBoston$7.4M
- Francisco MartyBoston$6.2M
- Stephen WalshBoston$5.4M
- Sophia KooBoston$4.9M
- Jennifer WangWorcester$2.7M
- David SnydmanBoston$2.6M
- Claudia MartorellSpringfield$2.4M
- Yoav GolanBoston$1.8M
- Robert FinbergWorcester$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.